Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2007
11/15/2007WO2007129712A1 Transdermally absorbable donepezil preparation
11/15/2007WO2007129701A1 Method of producing dry yeast containing s-adenosyl-l-methionine and composition for oral intake
11/15/2007WO2007129473A1 Bicyclic aryl derivative
11/15/2007WO2007129457A1 Therapeutic agents for alzheimer's disease and cancer
11/15/2007WO2007129427A1 Tansdermally absorbable preparation comprising anti-dementia agent
11/15/2007WO2007129111A1 Diazepine derivatives as 5-ht2a antagonists
11/15/2007WO2007128924A2 Aqueous tobacco leaf extract, uses thereof in the treatment of dependence
11/15/2007WO2007128752A1 Pyridyl compounds
11/15/2007WO2007128694A1 N-oxides of pyridylmethylpiperazine and -piperidine derivatives
11/15/2007WO2007128674A2 Muscarinic agonists to treat impulse control disorders
11/15/2007WO2007128493A1 Neuroprotective compounds and uses thereof
11/15/2007WO2007128462A1 Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
11/15/2007WO2007128459A1 Bicyclic tetrahydropyrrole compounds
11/15/2007WO2007128458A1 Bicyclic tetrahydropyrrole compounds
11/15/2007WO2007128344A1 Design and synthesis of biotinylated probes for n-acyl-ethanolamines
11/15/2007WO2007128088A2 Use of n-aminoimidazole cytoprotective compounds for treating cell death and/or gsk-3 mediated diseases
11/15/2007WO2007111982A3 Methods for treating cognitive and other disorders
11/15/2007WO2007109355A3 6,7,8, 9 -tetrahydro- 5h- pyrimido [4, 5-d] azepin-4-yl] -amine derivatives as modulators of trpvl for the treatment of pain
11/15/2007WO2007108744A3 Novel quinazolines as 5-ht6 modulators
11/15/2007WO2007108743A3 Novel quinazolines as 5-ht6 modulators ii
11/15/2007WO2007104867A3 Cosmetic, pharmaceutical, food and veterinary compositions whose activating action on genes of sirtuin type makes it possible to delay ageing in mammals and the harmful effects thereof
11/15/2007WO2007096076A3 Anti-amyloid immunogenic compositions, methods and uses
11/15/2007WO2007093624A3 Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
11/15/2007WO2007090141A3 Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
11/15/2007WO2007087151A3 Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction
11/15/2007WO2007075695A3 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
11/15/2007WO2007070504A3 Stable and palatable oral liquid sumatriptan compositions
11/15/2007WO2006100075A8 Use of an artificial sweetener to enhance absorption of nicotine
11/15/2007WO2003018754A3 Neural regeneration peptide and methods for their use in treatment of brain damage
11/15/2007US20070265449 Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
11/15/2007US20070265350 Method of identifying compounds useful to treat neuronal degenerative diseases
11/15/2007US20070265348 Therapeutic guanidines
11/15/2007US20070265342 2-[(2'S)-(2'-Amino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid; glutamate receptor agonist; antidepressant, anxiolytic agent; psychological, and psychiatric disorders
11/15/2007US20070265336 Application of L-N-Butylphthalide in Preventing and Treating Dementia
11/15/2007US20070265331 Such as (2S)-2-(3(S)-Acetylamino-3-((S)-sec-butyl)-2-oxo-pyrrolidin-1-yl)-N-[(1S,2R)-1-(3,5-difluoro-benzyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-4-phenyl-butyramide; inhibit processing of amyloid precursor proteins
11/15/2007US20070265328 2-(6-oxo-1,7-diaza-spiro[4.4]non-7-yl)-propionamides such as 4-(S)-hydroxy-5-(S)-[2-(S)-(1-isobutyl-6-oxo-1,7-diaza-spiro(S)-[4.4]non-7-yl)-propionylamino]-2-(R)-methyl-6-phenyl-hexanoic acid butylamide; inhibitors of aspartic proteases such as beta-secretase
11/15/2007US20070265327 For therapy of neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal
11/15/2007US20070265325 Nitro Indazole Derivatives
11/15/2007US20070265323 Compounds for the treatment of metabolic disorders
11/15/2007US20070265322 Compounds for the treatment of metabolic disorders
11/15/2007US20070265320 (2S,4S)-1-[[(4-carbamoylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile, for treating type II diabetes; increase glucagon-like peptide activity
11/15/2007US20070265319 Neuroprotectants; reduce side effect of neurotoxic agent; treatment of neuropathies resulting from chemotherapeutic agents used in the treatment of HIV and proliferative disease such as cancer and treatment of inflammatory diseases, neurodegenerative diseases
11/15/2007US20070265300 Pyridine Derivatives of Alkyl Oxindoles as 5-Ht7 Receptor Active Agents
11/15/2007US20070265294 Formulations and methods for vascular permeability-related diseases or conditions
11/15/2007US20070265285 Quinazolinone derivatives and their use as CB agonists
11/15/2007US20070265271 (8-Methyl-3,8-diaza-bicyclo[3.2.1]oct-3-yl)-[5-(4-nitro-phenyl)-furan-2-yl]-methanone; cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters; nervous system diseases; inflammation, pain; drug addiction
11/15/2007US20070265270 Cinnoline derivatives as phosphodiesterase 10 inhibitors
11/15/2007US20070265264 Thia-tetraazaacenaphthylene kinase inhibitors
11/15/2007US20070265263 Heterocyclic inhibitors of ERK2 and uses thereof
11/15/2007US20070265258 Quinazoline derivatives as phosphodiesterase 10 inhibitors
11/15/2007US20070265256 Phosphodiesterase 10 inhibitors
11/15/2007US20070265254 Naphthaline derivatives as H3 inverse agonists
11/15/2007US20070265251 Muscarinic Antagonists With Parp and Sir Modulating Activity as Cytoprotective Agents
11/15/2007US20070265241 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
11/15/2007US20070265208 Association of calpain inhibitors and reactive oxygen species trapping agents
11/15/2007US20070265202 Compounds That Modulate Trh Actions
11/15/2007US20070265194 Agents for the treatment of viral infections
11/15/2007US20070265188 LDL Receptor-Related Proteins 1 and 2 and Treatment of Bone or Cartilage Conditions
11/15/2007US20070264712 Expansion and differentiation of neural stem cells under low oxygen conditions
11/15/2007US20070264358 Methods and Compositions for Treating Mood Disorder
11/15/2007US20070264347 Agent for Treating or Preventing Diabetic Neuropathy
11/15/2007US20070264345 liquid crystal gel containing polyoxyethylene-glyceryl-trioleate, 26.7-40.0%, propylene-glycol, 13.3-20.0%, isopropyl myristate, 5.0-35.0%, ethanol, 0.01-10.0%, benzyl alcohol, 0.5-1.5%, a hyaluronic acid salt or complex 0.01-2.00%, and purified water, 12.5-26.5%; healing cosmetics
11/15/2007US20070264336 Hydrophilic/lipophilic polymeric matrix dosage formulation
11/15/2007US20070264282 Herpes virus strains for gene therapy
11/15/2007US20070264280 Compositions and Methods for Treating Neurological Diseases
11/15/2007US20070264276 Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
11/15/2007US20070264245 Compositions and minimally invasive methods for treating incomplete tissue repair
11/15/2007US20070264232 Cell populations which co-express CD49c and CD90
11/15/2007US20070264197 Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection reagents
11/15/2007US20070264195 Modulation of Activity of Neurotrophins
11/15/2007US20070264194 Peptides That Bind To Atherosclerotic Lesions
11/15/2007CA2651596A1 Percutaneous absorption preparations of antidementia drugs
11/15/2007CA2651296A1 Aqueous tobacco leaf extract, uses thereof in the treatment of dependence
11/15/2007CA2651033A1 Constrained compounds as cgrp-receptor antagonists
11/15/2007CA2650976A1 Bicyclic heteroaryl compounds as pde10 inhibitors
11/15/2007CA2650853A1 Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
11/15/2007CA2650255A1 Mglur5 modulators v
11/15/2007CA2650114A1 Mglur5 modulators i
11/15/2007CA2649917A1 Muscarinic agonists to treat impulse control disorders
11/15/2007CA2649479A1 N-oxides of pyridylmethylpiperazine and -piperidine derivatives
11/15/2007CA2642647A1 Compositions and methods for treatment of disorders of protein aggregation
11/15/2007CA2641100A1 Bicyclic tetrahydropyrrole compounds
11/15/2007CA2640806A1 Bicyclic tetrahydropyrrole compounds
11/14/2007EP1854880A1 Methods and reagents for modulating cholesterol levels
11/14/2007EP1854793A1 NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY
11/14/2007EP1854785A1 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
11/14/2007EP1854777A1 Hydroquinone long-chain derivative and/or phenoxy long-chain derivative, and pharmaceutical preparation comprising the same
11/14/2007EP1854486A2 Utilisation of neurotransmitter derivatives for manufacturing agents for treating neuroendocrinal diseases
11/14/2007EP1854480A2 Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
11/14/2007EP1854461A1 Prophylactic antistress agent
11/14/2007EP1853626A2 Amyloid-binding peptides, analogues and uses thereof
11/14/2007EP1853594A2 Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
11/14/2007EP1853593A1 Crystalline and amorphous 4-cyano-n{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride
11/14/2007EP1853576A1 Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
11/14/2007EP1853575A1 Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
11/14/2007EP1853572A1 Fluorinated phno and analogs thereof
11/14/2007EP1853566A1 Cinnoline compounds and their use as liver x receptor modulators
11/14/2007EP1853564A1 Novel quinoline derivatives as potassium ion channel openers
11/14/2007EP1853553A1 Substituted hydroxyethylamines
11/14/2007EP1853349A1 Composition for treating mental health disorders
1 ... 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 ... 1833